Efanesoctocog alfa in children with hemophilia A reduces bleeding
1. In this randomized controlled trial, a prophylactic weekly dose of efanesoctocog alfa (ALTUVIIIO) resulted in sustained factor VIII activity ...
Tag: factor VIII
Valactogene roxaparvovec for hemophilia A demonstrates factor VIII durability for two years
1. At least two years after gene transfer, valoctocogene roxaparvovec demonstrated durability of factor VIII activity and bleeding reduction in ...
Valoctocogene roxaparvovec gene therapy efficacious for hemophilia A treatment
1. The adeno-associated virus 5 (AAV5)-based gene therapy, valoctocogene roxaparvovec (AAV5-hFVIII-SQ), resulted in sustained factor VIII production, reduced bleeding rates, ...